CartiHeal Announces Positive Interim Analysis Results of Agili-C™ IDE Study

December 9, 2019

CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today that the external and independent Endpoint Adjudication Committee (EAC) performed the first Interim Analysis (IA) on the study data following enrollment of the 250th Subject into the study. The EAC reviewed the IA safety and efficacy results and recommended to stop accrual for anticipated success. You can read more here.


Please reload

Please reload

Recent Posts

CartiHeal Performs First Agili-C™ Cartilage Repair Implantation Procedure in Maryland

October 15, 2019

Please reload

Featured Posts
Follow Us
Please reload

Search By Tags